Elad Kedar
CEO
Orasis Pharmaceuticals
Orasis Pharmaceuticals develops QLOSI™, an ophthalmic eye drop formulation designed to treat presbyopia, a condition that causes blurred near vision due to the aging of the eye's crystalline lens. This product aims to enhance visual acuity for over 128 million people in the U.S. affected by this progressive condition.
- Biotechnology
Updated 22 months ago
Funding
Raised to date
$130.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Presbyopia, an age-related condition affecting over 128 million people in the U.S., causes blurred near vision due to the stiffening of the eye's crystalline lens. This makes everyday tasks like reading and using smartphones difficult.
Solution
Orasis Pharmaceuticals is developing QLOSI™, an ophthalmic eye drop designed to improve near visual acuity for individuals with presbyopia. QLOSI™ aims to provide a non-surgical solution to enhance focus on near objects, addressing the limitations caused by the aging eye. By improving the eye's ability to focus, QLOSI™ seeks to restore clear near vision and improve the quality of life for those affected by this progressive condition.
Target Audience
The primary target audience includes the over 128 million people in the U.S. who suffer from presbyopia, as well as eye care providers seeking non-surgical treatment options for their patients.
Features
- Ophthalmic eye drop formulation
- Designed to treat presbyopia
- Intended to improve near visual acuity